ArticleFrontiers in bioengineering and biotechnology2026
Effects of low-serum adaptation on growth and protein expression in stably lactoferrin-overexpressing mammary alveolar cells.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Long-term culture with high serum concentrations increases culture costs, accelerates cell senescence, and limits industrial-scale applications. Serum reduction adaptation is an effective solution for addressing these issues. In this study, we aimed to investigate the effects of two low-serum adaptation strategies on the growth and lactoferrin expression in stably LTF-overexpressing bovine mammary alveolar cells transfected with large T antigen (MAC-T). Methods: Two adaptation protocols of serum concentration reduction and dual-medium gradient adaptation were implemented to progressively reduce serum dependence in MAC-T cells. Results: Under both adaptation modes, cells maintained stable proliferation at 1% fetal bovine serum (FBS). At the 0.5% FBS (serum reduction) and 10% basal control medium, equivalent to 1% FBS in dual-medium adaptation stages, adding 10% knockout™ serum replacement and 1% insulin-transferrin-selenium 5 increased the specific growth rate by 30%, enabling robust cell growth under low-serum conditions. Conclusion: Across all the low-serum conditions, cells retained typical epithelial morphology (cytokeratin 18-positive) while exhibiting consistent
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.